Multimodal nanoparticle imaging agents: Design and applications by Burke, Benjamin P.. et al.
Phil. Trans. R. Soc. A. 
doi:10.1098/not yet assigned 
 
Multimodal nanoparticle imaging agents: Design and 
Applications 
Benjamin P. Burkea,b, Christopher Cawthorneb,c and Stephen J. 
Archibalda,b* 
aDepartment of Chemistry, bPositron Emission Tomography Research Centre, cSchool of Life Sciences, 
University of Hull, Cottingham Road, Hull, HU6 7RX, UK 
Keywords: Nanoparticle, Molecular Imaging, PET, SPECT, MRI, Optical 
Summary 
Molecular imaging, where the location of molecules or nanoscale constructs can be tracked in the body to report on 
disease or biochemical processes, is rapidly expanding to include combined modality or multimodal imaging. No single 
imaging technique can offer the optimum combination of properties (e.g. resolution, sensitivity cost, availability).  
The rapid technological advances in hardware to scan patients, and software to process and fuse images, is pushing the 
boundaries of novel medical imaging approaches, and hand-in-hand with this is the requirement for advanced and specific 
multimodal imaging agents. These agents can be detected using a selection from radioisotope, magnetic resonance and 
optical imaging, amongst others. Nanoparticles offer great scope in this area as they lend themselves, via facile 
modification procedures, to act as multifunctional constructs. They have relevance as therapeutics and drug delivery 
agents that can be tracked by molecular imaging techniques with the particular development of applications in optically 
guided surgery and as radiosensitisers.  
There has been a huge amount of research work to produce nanoconstructs for imaging and the parameters for successful 
clinical translation and validation of therapeutic applications are now becoming much better understood. It is an exciting 
time of progress for these agents as their potential is closer to being realised with translation into the clinic. The coming 
5-10 years will be critical, as we will see if the predicted improvement in clinical outcomes becomes a reality. Some of 
the latest advances in combination modality agents are selected and the progression pathway to clinical trials analysed. 
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1. Multimodal imaging – general introduction and applications 
of multimodal imaging nanoparticle agents 
 
Molecular imaging has developed over the past 30 years in parallel with the advances of medical imaging technologies.  
PET/CT scanners arrived into clinical use in the early 1990s; combining the molecular detection component with an 
anatomical technique to provide improved data sets to the clinicians and demonstrating the potential for multimodal 
imaging. Many radiology/ nuclear medicine departments are now using PET/MRI as the next generation technology, 
however, there is still much work to be done to use combined molecular imaging techniques to their full potential. There 
are also complications as to how they fit into clinical pathways, the consistency of data production and imaging protocols, 
but the potential is clear. 
Whilst the technology for combined modality scanners or the fusing of image data from separately collected 
multiple image modalities has advanced, there have been more limited advances in the multimodality imaging tools in 
clinical use to allow the full potential of multimodal imaging to be reached. Their development is complicated by the fact 
that optimisation for a single imaging technique is not appropriate, it must be for the combination, and the chemical 
standards/ parameters have not been set in terms of isotopes, wavelengths for optical or MRI pulse sequences. 
The driver behind the production of multimodal scanners and agents is to balance the advantages and 
disadvantages of different imaging techniques i.e. sensitivity of detection vs. resolution of the image. Table 1 shows 
many of the key molecular imaging techniques and their properties. The key applications are in diagnosis of disease, 
patient stratification and the therapy response. Mulitmodal imaging is also an excellent tool for drug development and 
radiolabelling of constructs can be used to obtain ADME and PK characteristics of novel molecules or constructs that are 
in development as therapeutics 
Nanoparticles are ideal for these applications with large surface areas that can be functionalised to introduce 
multiple modality reporters and targeting vectors to modify localisation properties. The particle size, morphology and 
surface chemistry can also be modified to influence their behaviour in vivo.1 The assessment of in vivo characteristics 
including biodistribution, clearance and targeting are essential for successful translation.2  
No single molecular imaging modality has the capability to offer all of the required data to fully characterise the 
properties of an administered agent.3 Optical techniques have limited tissue penetration in vivo, MRI has high resolution 
but low sensitivity whilst radioisotope imaging techniques offer much improved sensitivity but relatively poor resolution. 
Multimodal imaging validation can expedite progress of nanomaterials to clinical trials and also provides key design/ 
development data at the preclinical stage. This can streamline development and, clinically, can offer a secondary mode of 
analysis in excised tissue or be used to guide surgery.4  
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2. Multimodal imaging agents – formation of and key example 
applications  
2.1. PET or SPECT with MR 
The combination of nuclear imaging techniques (PET or SPECT) with magnetic nanoparticles has been an active area of 
research over the last decade. The design of radioisotope/MR imaging agents is generally carried out by starting with a 
magnetic nanoparticle core and either attaching radioactive isotopes to the surface, or incorporating them into the core. 
Using magnetic nanoparticle contrast agents in MRI is relatively low sensitivity and whilst variable contrast can be seen 
in high uptake tissues, quantified biodistribution is not possible. The radiolabelling of MR contrast agents for PET (or 
SPECT) imaging can allow them to be assessed at tracer doses in ‘phase 0’ clinical trials, and to demonstrate that MRI is 
appropriate for routine clinical procedures at required higher doses of the agent. Nuclear imaging also allows the tumour 
targeting and drug delivery properties to be rapidly determined non-invasively and with minimal animal use.5 
 The simplest way to radiolabel a nanoparticle is via the direct interaction of the radioisotope with the surface of a 
pre-formed nanoconstruct. The term ‘chelator free’ generally refers to the use of radioactive metals that form stable 
interactions directly with the surface or core of nanoparticles. This methodology allows the direct labelling of constructs 
without significant alteration of surface properties, making it attractive for use when the parent nanoparticle has already 
been optimised for various applications, e.g. targeting, magnetism or drug delivery. For example, Voulgari et al. 
developed a PMAA-graft-PEG copolymer-derived iron oxide nanoparticle system for the delivery of cisplatin to tumours 
which showed improved therapeutic effect in vivo compared to free cisplatin, particularly in the presence of an external 
magnetic field.6 Final step chelator-free gallium-68 radiolabelling and dynamic PET imaging indicated the increased 
potency in the presence of a magnetic field was likely to be caused by an increase in internalisation of the cisplatin-loaded 
carrier rather than a direct increase in nanoparticle (and therefore drug) concentration in the tumour. Chelator free 
methodologies can also be used to directly understand clinically approved nanoparticles. Ferumoxytol, an FDA approved 
nanoparticle, has been successfully radiolabelled with a range of radiometals by a heat-induced method to allow highly 
sensitive evaluation,7, 8 although this method is only feasible when nanoconstructs are stable with respect to heat. Loudos 
and co-workers have used chelator-free methods for imaging of 99mTc labelled magnetic nanoparticles using a planar 
gamma camera,9-11 comparing the biodistribution of cobalt ferrite and magnetite nanoparticles9, 11 and quantifying the 
increase in tumour uptake with actively targeted nanoparticles.10 Cheng et al. radiolabelled FeSe2 doped Bi2Se3 
nanosheets with copper-64 to form a stable system,12 PET imaging was used to offer dynamic information on tumour 
accumulation over 24 hours. In a similar manner, Lee et al. used 99mTc radiolabelled SPIONs to quantify increased 
tumour localisation when using Lipiodol as a carrier.13 
Radiometal isotopes for PET (or SPECT) can be attached on the nanoparticle surface using a chelator, either 
final-step or two-step. The majority of reported examples of final step chelator based radiolabelling use the combination 
of copper-64 and DOTA,14, 15 likely based on the availability of chelator precursors rather than designed compatability.16 
An alternative method for forming chelator based radiolabelled nanoparticles is the initial radiolabelling of a bifunctional 
chelator (BFC, chelating agent with a reactive group) followed by conjugation of the radiometal complex to the 
nanoparticle. The advantage of this method is that the radiometal is stably bound to the chelate before attachment to the 
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nanoparticle, hence other surface coordination interactions are not possible. Chelate/metal stability can be assessed prior 
to conjugation and so only the stability of chelator attachment would need to be assessed for the formed conjugate with 
the nanoparticle. Louie and co-workers developed one of the first radiolabelled magnetic nanoparticle systems using this 
methodology.17 Copper-64 radiolabelling of an amine functionalised DOTA derivative was performed before conjugation 
to a dextran sulfate nanoparticle. An alternative approach is to use a BFC which can bind to the nanoparticle core. Torres 
and co-workers have developed a bisphosphonate bifunctional system which, by modification of the chelating unit, can 
bind to either 99mTc for SPECT imaging or 64Cu for PET imaging (see Figure 1).18, 19 These units can then coordinate 
directly to the metal oxide core surface via strong bisphosphonate interactions with the iron atoms.20  
In an interesting study, Wang et al. introduced multiple radioactive isotopes in the same construct at different 
positions to track the in vivo behaviour and metabolism of the nanoparticle.21 59Fe was used to label the core, 111In 
chelated to DTPA was added to the lipid (DMPE) coating along with 14C-oleic acid as a stabiliser. In vivo biodistribution 
studies were used to see how the different components were processed. As expected,22 the oleic acid used as a surfactant 
does not remain attached in vivo after only 10 minutes, whereas 59Fe and 111In largely correlate, assuming initially that the 
DTPA-DMPE remains attached to the nanoparticle. However, significant differences were noticed in kidney and robust 
control experiments (administration of 111In-DTPA-DMPE alone) showed a similar biodistribution potentially caused by 
micelle formation, suggesting instability of chelator attachment. This type of multi-isotope study where different 
components can be separately tracked is complex to set up but can give useful and accurate information about the 
processing of nanoparticles in vivo. 
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2.2. Optical/MR 
Optical imaging is often used for in vitro biological experiments as, compared to other imaging techniques, there are 
many practical advantages; simplicity of use with a live readout, open timeframe, availability of (and ability to design) a 
range of fluorophores with tuned properties, and lack of ionising radiation.23 Limited light penetration prevents non-
invasive deep tissue in vivo use, but it is clinically important in applications such as fluorescence guided surgery. Optical 
imaging of MR contrast agents overcomes the low sensitivity of MR imaging and allows the collection of real-time 
information during in vitro assessment, allowing for rapid screening and identification of key characteristics for iterative 
design. In addition, there is the potential for one agent to be used for non-invasive MR imaging to determine tumour 
localisation and characteristics, followed by intraoperative optical imaging to ensure complete tissue removal. 
 The first and most successful approach to the formation of optical/MR imaging agents is via conjugation of an 
organic dye on the surface of an iron oxide nanoparticle. This allows for retention of the core properties of the previously 
designed nanotechnologies with only limited chemical modification. Josephson and co-workers labelled cross-linked iron 
oxide nanoparticles (CLIOs) with a Cy5.5 dye for gliosarcoma imaging, allowing for both non-invasive and 
intraoperative imaging pre-clinically (see Figure 2).24 Surface functionalisation of magnetic nanoparticles with organic 
dyes has limitations, often caused by low photostability. Increasing sensitivity and utility of the optical properties has 
been a focus of many studies, for example, by introducing additional multifunctionality to the system. This has recently 
been demonstrated using multifunctional gold and iron oxide composites which are conjugated with both a fluorescein 
organic dye and a europium(III) complex which could be targeted to the folate receptor and a calcium sensor.25 This 
highly complex functionality allowed for high sensitivity cell counting, however, increased nanoparticle complexity 
significantly limits potential clinical translation. An alternate route to increased sensitivity is via surface encapsulation of 
the organic dyes instead of conjugation, leading to reduced photobleaching and the potential to increase dye loading 
content.26-28 With the development of organic dye functionalised nanoparticles, there is also a significant recent move 
towards near exclusive use of near infra-red (NIR) dyes to allow for increased tissue penetration of the signal.29  
 An alternate strategy for the formation of optical/MR multimodal agents is through the use of quantum dots 
(QDs). Using QDs ensures high sensitivity fluorescence due to their high photostability, quantum yield and extinction 
coefficients. There are a range of methods for the formation of QD based optical/MR probes including using 
gadolinium(III) chelates and iron-oxide nanoparticles, amongst others.30, 31 A recent interesting example describes the 
formation of a graphene QD which can be conjugated to iron oxide nanoparticles as MRI contrast agents, after which the 
nanoprobe can be both functionalised with folic acid for cancer targeting and loaded with doxorubicin for therapy.32 This 
agent allowed in situ monitoring of cellular uptake and drug release via FRET. 
 The most recent major addition to the library of optical/MR imaging agents are based on upconversion 
nanoparticles (UCNPs) in which high energy visible light can be emitted when excited by NIR light. UCNPs have the 
advantage of significant stability, photobleaching resistance and very high sensitivity, with single particle imaging having 
been demonstrated. Significant materials chemistry research efforts have been focused on methodologies for the 
formation of UCNPs coupled with magnetic nanoparticles without disrupting the optical or magnetic properties 
respectively.28, 33, 34 Additionally, UCNPs often contain lanthanide cores, which allow for direct replacement with MR 
responsive gadolinium(III) ions, without causing significant structural change.35, 36  
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2.3. PET or SPECT with Optical 
The combination of optical with nuclear imaging allows for additional information to be gathered on a single construct. 
Nuclear imaging is used for high sensitivity data to give dynamic tracer information at short time-points, optical imaging 
allows for longitudinal imaging to assess biodistribution at further time points. A radioisotope is often added to an optical 
imaging nanoparticle to give high sensitivity biodistribution data in a similar manner to that which is done with MR 
agents. A key application for PET(SPECT)/optical imaging agents is for image guided surgery in which nuclear imaging 
is carried out to determine localisation and the optical imaging is used intraoperatively to mark diseased regions to aid in 
surgical removal. 
 Early examples of radiolabelling of inorganic nanoparticles, including optical imaging agents, focused on 
chelator based radiolabelling and surface modification, for example, Chen et al. labelled quantum dots (QDs) with 64Cu 
using surface functionalised DOTA chelators.37 However, more recently, focus has moved away from chelator based 
approaches, with the aim of imaging the inherent nanoparticle without having to make structural modifications which 
could affect its properties. Hu et al. and subsequently Sun et al. synthesised radiolabelled gold nanoclusters and QDs 
respectively by doping 64Cu via a cation-exchange reaction in a chelator-free protocol.38, 39 Introduction of the radioactive 
isotope also causes Cerenkov resonance energy transfer, providing self-illuminating nanoparticles and avoiding the 
usually required external excitation photon. Direct replacement of elements can also be carried out to form radiolabelled 
nanoparticles, for example by the introduction of 198Au in to gold nanoparticles without modification of the chemical 
structure.40 Radiolabelling has allowed for imaging biodistribution assessment of various shaped nanoparticles 
(nanospheres, nanodisks, nanorods, and cubic nanocages) to determine the optimal shape for tumour targeting.41 
Analogously, Zhou et al. radiolabelled CuS nanoparticles with 64Cu to form the identical structure, forming a self-
illuminating an optical/PET imaging agent which could be used for photothermal ablation therapy.42  
The alternative approach for forming PET or SPECT with optical multimodal imaging agents is by dual 
modification on non-optical based nanoparticles. Lin et al. formed an optical/PET agent by surface attachment of chelator 
based 64Cu and a Cy5.5 dye to ferritin nanocages.43 Similarly, Blanco et al. developed a SapC-DOPS nanoparticle 
functionalised with an organic dye and radiolabelled with 124/127I.44 PET imaging was used to quantify targeting to 
glioblastoma in vivo, with the optical dye potentially acting as a surgical marker to ensure all cancerous tissue is removed 
during invasive brain surgery. 
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2.4. Trimodal imaging agents 
 Imaging agents which combine an optical/MR agent with a radioactive isotope for PET or SPECT are often 
referred to as trimodal and are often designed due to their complementary features or to use nuclear imaging to 
understand previously designed agents.45 For example, using a trimodal probe, a biological system can be rapidly 
screened using high throughput optical imaging, if an interesting system or disease model is selected for non-invasive 
imaging, it can be radiolabelled for dynamic high sensitive short-timeframe imaging, followed by longitudinal MR 
imaging. However, it must be noted that this increased complexity presents significant chemical design challenges and 
subsequent regulatory hurdles. 
 One of the simplest, and earliest, methods designed for the formation of trimodal imaging agents is decoration of 
the surface of iron oxide nanoparticles with both an organic dye and a radioactive isotope, often a using a radiometal 
/chelator approach. Xie et al. designed a system for PET/MRI/optical imaging which uses final step 64Cu radiolabelling of 
DOTA and a cy5.5 dye functionalised iron oxide nanoparticles which have also been modified for active tumour targeting 
using human serum albumin (HSA).46 Having a trimodal system allows for simple assessment of signal overlap to give an 
indication of material stability, ex vivo organ analysis showed little correlation between near infrared fluorescence (NIRF) 
imaging and the PET image and whilst this was attributed to the high background of NIRF imaging, the data is also 
consistent with radiolabel chelation instability (which was not assessed in the study). By changing any single parameter, 
magnetic core, dye, radioisotope, or active targeting agent, an entirely different system can be designed with similar 
target properties. For example, Hwang et al. used a nucleolin targeted cobalt ferrite nanoparticle which was radiolabelled 
via NOTA based 67Ga chemistry for SPECT imaging and conjugated with rhodamine for optical imaging (see Figure 3).47 
One conclusion from the studies is that, from a simplicity perspective, when radiolabelling, a chelator-free approach is 
preferred, as, for example, demonstrated by Stelter et al. in their formation of trimodal agents for both PET and SPECT 
with 68Ga and 111In respectively.48 
Alternatively, the nanoparticle core can be replaced with an UCNP derivative from which a trimodal agent can 
be built. Lee et al. designed an erbium(III) and ytterbium(III) doped NaGdF4 UCNP which could be both radiolabelled 
with 124I for PET imaging and also integrin targeted using surface RGD peptides for angiogenesis imaging.49 In this study, 
the PET imaging was used to quantify tumour uptake and were therefore able to demonstrate that selectivity via blocking. 
It is also possible to design a trimodal imaging agent in which the core serves no imaging function, with imaging agents 
grafted on the surface. Li et al. designed a trimodal theranostic liposome system in which both gadolinium(III) DOTA 
agents and a NIR dye were attached on the surface, whilst 99mTc for SPECT imaging was internally encapsulated along 
with doxorubicin, alternatively, a PET imaging version could be produced using surface conjugated 64Cu DOTA based 
radiolabelling.50 Multimodal in vivo imaging studies demonstrated the potential of this system in squamous cell 
carcinoma imaging of head and neck (SCCHN) tumour xenografts, however, this was only achieved via intra tumoural 
administration of the imaging agent in the reported study. 
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3. Translation to clinical trials 
Despite slow progress,51, 52 the parameters for successful translation to clinical trials are now becoming better understood 
for nanoparticle constructs. Unsurprisingly the most rapidly translated constructs are either modifications of nanoparticles 
that are in current clinical use (or have previously had approval) or encapsulated formulations of known therapeutic drug 
molecules.53 The latter category, which includes a variety of drug delivery agents, many of them passively targeted, in 
liposomal formulations. Doxil (a doxorubicin delivery agent) was approved in 1995, and more recently Onivyde (an 
irinotecan delivery agent) was approved in 2015. This is the main area of clinical trial activity. However, inorganic and 
multimodal nanoparticles are coming to the fore in some recent advances.54 
 
3.1 Recent and ongoing clinical trials 
 
In terms of inorganic nanoparticles, the iron oxide nanoparticles have the greatest wealth of clinical data. A key benefit 
for this approach is the well characterised toxicological profiles and the compatibility of iron oxides with metabolic 
processing due to the requirement for iron in the human body.55 These agents have long established safety profiles going 
back over 20 years, with uses as iron replacement therapies, and hence toxicological issues and potential complications 
are well understood. The iron oxide nanoparticles (Endorem and Resovist), that were used as T2 contrast agents did not 
enter into widespread routine use, leading to them being discontinued as products. Ferumoxytol was originally approved 
for the treatment of iron deficiency but has subsequently been used in cancer imaging studies (MR T2 contrast agent) and 
is now being investigated as a multimodal imaging agent through a variety of studies to radiolabel the construct. 
 
As well as MR/PET advances (many of which are linked to the increasing availability of PET MRI integrated clinical 
scanners) there are also many developments in the combination of optical imaging with radioisotopes. The Cornell Dots 
are the most obvious success in this area of research, in terms of translation to clinical trials.56 The initial study showed no 
toxic or adverse events, prompting an expansion of this work in 2014 to the currently ongoing clinical trials. These agents 
combine the use of targeting peptides, radioisotopes and an optical dye (cyanine 5 dye) into a silica nanoparticle. There 
are many lessons to be learnt by examining the initial research approach that the researchers followed and the 
modifications that were made to ensure translational work was viable. A key issue was the modification of the size of the 
particles- the group started off with particles in the 30-50 nm range but later reduced this to the 5-7 nm particle size range 
to modify the excretion and tissue retention profile, ensuring both safety and effective targeting. The iodine-124 isotope 
was used as a long-lived PET emitter (although as the decay is only 25.6% positron emission, future protocols are more 
likely to utilise the now widely available zirconium-89 isotope), see Figure 4. These compounds are not quantum dots 
which have raised concerns in the past with the toxic materials, such as cadmium, that were included as components in 
the first generation of these materials.4 Although quantum dots have high stability, it is an unnecessary risk for clinical 
use, hence less toxic elements such as zinc are now being used in the next generation QDs to allow the excellent optical 
properties to be exploited.57 
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An important trial that is ongoing is the AGUiX trial for radiosensitisation using a silica nanoparticle (ca. 5 nm diameter) 
with chelated gadolinium on the surface using DOTA chelators that offer contrast in MR imaging studies.58 The 
developmental process is an interesting one to follow as it is an excellent example of the tools that are now becoming 
more recognised in the approval process for nanomedicines, with multimodal imaging a key component. Clinical trials 
started in mid-2016 for applications in radiosensitisation of multiple brain metastases.59-61 The Tillement group and their 
collaborators have been working over the past five years to develop radiolabelled derivatives of this construct, both to 
provide data on the constructs for the trials and to further develop applications such as tagging large biomolecules with 
the ultrasmall nanoparticles for multimodal imaging.62, 63 There are two key criteria that must be considered when 
utilising a radiosensitiser; what is the timescale for optimal localisation/ tissue concentration and how should the radiation 
beam be applied (clinical beam parameters and dose administered).59 Investigation of these parameters is possible using 
zirconium-89 labelled constructs.63 
 
In terms of other clinical trials, thermal ablation (hyperthermia) has also been a key development area and may point to 
some of the other types of particles that may be repurposed for imaging and targeting. The use of silica/ gold 
nanoparticles (Aurolase) in lung tumours and iron oxide nanoparticles (Magnablate) in prostate tumours are examples of 
this application.55 As clinical trial processes can be started many years in advance, we do not always see rapid response, 
but the trends to small actively targeted particles that can be applied vascularised tumours are likely to be observed in 
future developments with the concurrent use of MR / radionuclide imaging as key components in the developmental 
pathway. 
 
3.2 Factors to consider for clinical translation 
 
Although nanoparticles and nanotechnology have caught the public interest, both in fact and in fiction, there are valid 
concerns about their use which need to be considered.64 Regulatory and public bodies are particularly concerned about the 
toxicity issues, that could cause some different problems to small molecules and biologic as drugs, and the impact on the 
environment of such formulations.65 Any planned clinical translational project will need to mitigate these issues and 
provide the data required to ensure both that the concerns of public bodies are fully addressed but also that the system has 
been appropriately optimised in the preclinical setting.66 At this stage the particle size effects and biodistribution can be 
determined using imaging techniques. It is also becoming much clearer to regulators what they should be looking for in a 
data set. Imaging is the key technology that will facilitate rapid translation by providing much of the ADME data in 
animal models and informing early phase (“phase 0”) trials It is also worth considering that there are challenges in the 
production and manufacturing of nanomedicines51, including the subtle effects of physical conditions on the variability of 
the particle properties and there are few facilities appropriately tooled for the production of such materials in bulk to 
GMP standards. 
 
The low mass modifications from radiolabelling approaches are appealing and give the required sensitivity of detection. 
The key reasons why this is attractive are: 
(1) The particles can be treated as essentially the same construct with a non-disruptive radiolabel for tracking  
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(2) Tracer level studies can reduce safety concerns and subsequently be used facilitate patient selection for trials. 
(3) Assessment of PK and ADME parameters is possible. 
(4) Dosing level can be determined (and time to treatment for radiotherapies) 
 
There are other opportunities including low cost fast fail screening of constructs in small scale human trials and a move 
away from rodent models to either large animal studies (e.g. pigs) with fewer animals required or potentially the use in 
veterinary clinical trials in companion animals.67-69 Overall, it is clear that accurate and effective in vivo tracking of 
nanoconstructs using radionuclide labelling can be a facilitating technique for progression to clinical trials, and this is 
even more effective when combined with optical imaging techniques for ex vivo tissue analysis and MR for longitudinal 
imaging.5, 70  
 
 
4. New applications and developments 
The predicted explosion in the use of nanoparticles for clinical imaging and therapy has not yet occurred. This is mainly 
due to the unanticipated challenges in terms of optimisation of the systems. In retrospect is seems obvious that a more 
complex system should take a longer time to have impact, particularly in a crowded preclinical scientific development 
space.55, 71 The combination of novel targeting approaches and therapy is compelling and has now been implemented in 
approaches that have transitioned to trials in man. 
 
A lot of the information to inform the best methodology for clinical development is now available in the literature 
(although not always considered in as much detail by researchers as it should be). The message is clear for any particles 
that require circulation and active targeting; a size less than 10 nm with a renal clearance pathway is the approach that has 
been validated. Particles that localise passively by enhanced permeability and retention (EPR), target the liver/lungs or 
are delivered by direct injection will have larger optimal size profiles and different shapes. Also, an under considered 
issues is the formation of protein corona on the surface of the nanoparticles, this influences the circulation time and the 
overall in vivo properties (and can vary between species/ particle types). 
 
The progression to clinical trials of modified Ferumoxytol, gold nanoparticle constructs, the silica particles (such as the 
Cornell dots) and the multi-Gd AGuIX systems shows the pathways that can be adopted effectively. Applications, beyond 
drug delivery with liposomal and micellar formulations, that are most active in current clinical trials are hyperthermia 
(thermal ablation), optically guided surgery and radiation sensitisation.72-74 The approach of validating delivery using 
nuclear medicine techniques is very useful and may become a prerequisite for trial approval in the future. A good 
example of how this can work is seen in the chelator free labelling methods for radiolabelling of Ferumoxytol with a 
variety of radionuclides.7 Ferumoxytol is an example that shows minimal disruption of the construct on addition of the 
radiolabel and hence a potentially rapid pathway to approval for trials and it may have applications in tumour imaging.75, 
76 Some of the most exciting new opportunities are in optically or radiation guided surgical interventions. This allows 
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excision of the maximal amount of tumour tissue and minimises removal of healthy tissue to ensure the best outcome. 
Radiation sensitisation is a key area for development with the gadolinium and the gold nanoparticles (as already 
discussed). There are also opportunities to use such labelling strategies to validate novel administration methods for drugs 
such as inhalation or direct injection which can be validated, characterised and optimised using this strategy.77, 78 
 
5. Future perspective 
 
It has been stated that nanotechnology has underperformed in its translation from laboratory bench to clinical impact. As 
with many scientific advances, the discovery is only a first step along the route to understanding and optimising these 
materials for the applications. Nanomaterials have inherent complicating factors in comparison to small molecule drugs 
which have to be understood and analysed throughout the development process. 
 The selected research discussed herein shows that understanding has significantly increased of the impact of 
particle size/shape, coating and functionalisation on the material properties. Also the analysis methods in vivo are now 
more clearly defined to allow better selection/ optimisation process for the nanoconstructs. Multimodal imaging provides 
the information that underpins this and sits centrally to the process of translating nanoparticles into a variety of clinical 
applications from diagnostic imaging to therapeutic drug delivery. 
It is likely that further imaging combinations will be developed and a greater degree of multi-functionality will 
be introduced for new nanoparticles in the future. Even if the imaging aspects are only used for validation at an early 
developmental stage, rather than in the medical use of the final construct, they are of high value to justify progression. 
The additional information offered from the combination of imaging techniques could also be used at the clinical stage in 
patient stratification or even therapy response introducing greater flexibility in the development pathway, and minimal 
alteration of the nanoconstructs to repurpose them. 
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Table 1 – Comparison of the key characteristics of the most common imaging techniques used in multi-modal imaging. 
Modality Energy measured Spatial Resolution 
(mm) 
Relative 
Sensitivity 
Preclinical 
Use 
Clinical Use Advantages Limitations 
PET -rays 1-2 (pre-clinical) 
6-10 (clinical) 
Excellent Yes Yes High sensitivity 
Quantitative 
Dynamic 
Cost 
Availability 
SPECT -rays 0.5-2 (pre-clinical) 
7-15 (clinical) 
Good Yes Yes Established clinical facilities 
Good sensitivity 
Targeted imaging tracer availability 
Semi-quantitative 
MRI Radio waves 0.01-0.1 (pre-clinical) 
0.5-1.5 (clinical) 
Poor Yes Yes Established clinical facilities 
High spatial resolution 
Targeted imaging tracer availability 
Low sensitivity 
Optical Visible to infrared 
light 
1-5 Good Yes No High throughput 
Low cost 
Limited tissue penetration 
  
 
Figure 1 – PET/MR images of a copper-64 radiolabelled iron oxide nanoparticle demonstrating co-registration of lymph 
node uptake.18 
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Figure 2 – Uptake of Cy5.5 tagged optical/MR multimodal nanoparticles in GFP-expressing 9L glioma. (A) White light 
image, (B) GFP channel and (C) Cy5.5 channel.24 
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Figure 3 – Multimodal in vivo and ex vivo imaging using 67Ga labelled cancer targeting cobalt ferrite nanoparticle. (A) 
SPECT, (B) MR and (C) optical imaging.47 
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Figure 4 – PET imaging of particle distribution and tumour uptake after systemic injection of the 124I-cRGDY–PEG–C 
dots (A) CT scan with the metastasised tumour indicated by the arrow (B) PET image 4 hours after injection showing the 
localisation of the particles (including at the tumour margin) (C) co-registered PET-CT at 4 hours (D) co-registered PET-
CT at 24 hours (E) 18F-FDG PET-CT image to show the metastasised tumour.56 
 
